The Cooper Companies announced its financial results for the fiscal second quarter ended April 30, 2025, reporting consolidated net sales of $1,002.3 million, an increase of 6% reported and 7% organically. This performance was driven by double-digit growth in CooperVision's daily silicone hydrogel portfolio and CooperSurgical's office and surgical portfolio.
CooperVision's net sales reached $669.6 million, up 5% reported and 7% organically, with daily silicone hydrogel lenses growing 10% organically and myopia management revenue up 35% organically to $25 million. CooperSurgical posted net sales of $332.7 million, up 8% reported and 7% organically, with office and surgical sales growing 13% and fertility sales growing 3%.
The company's non-GAAP diluted earnings per share for Q2 2025 was $0.96, up 14% year-over-year. CooperCompanies updated its fiscal year 2025 guidance, raising non-GAAP EPS to $4.05 to $4.11, representing 10% to 11.5% growth. However, it adjusted consolidated organic revenue growth to 5% to 6%, reflecting a reduction in contact lens market growth forecast to 4% to 6% and fertility market growth to low single digits.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.